Platform Collaboration Programs (Sep 2024)
Not Disclosed
Discovery/PreclinicalConfidential - Multiple programs
Key Facts
Indication
Not Disclosed
Phase
Discovery/Preclinical
Status
Confidential - Multiple programs
Company
About Generate Biomedicines
Generate Biomedicines is at the forefront of integrating machine learning, biological engineering, and medicine to create a new paradigm in drug discovery called Generative Biology™. Its proprietary platform learns from millions of proteins to generate novel therapeutics with specific functions, drastically accelerating R&D. The company has advanced a Phase 3 anti-TSLP antibody for severe asthma, built a diverse preclinical pipeline in oncology and immunology, and secured strategic collaborations, positioning it as a leader in AI-driven biotherapeutics.
View full company profileTherapeutic Areas
Other Not Disclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Multiple Preclinical Programs | Generate Biomedicines | Preclinical |
| Platform Collaboration Programs (Jan 2022) | Generate Biomedicines | Discovery/Preclinical |
| AVA7100 | Avacta Group | Preclinical |